Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI

University of Toronto

$25,000.00

A multi institutional study evaluating the role of the gut microbiome on immune checkpoint inhibitor efficacy and toxicity in advanced solid tumors

FY 2018-19

Summary
Immune checkpoint inhibitors have improved survival for many patients with advanced cancers. However, these treatments do not work for all patients and we do not yet know how to best select patients for these treatments. In addition, many patients experience severe toxicities from immune checkpoint inhibitors. The type of bacteria in the human gut plays an important role in the immune system and may play an important role in determining whether a patient may benefit from treatment with immune checkpoint inhibitors and/or experiences toxicity. Our project will focus on further characterizing the gut bacteria involved in the activation of the immune system both in the response against tumors and in the development of toxicities. We will also test whether altering the bacteria in the gut may provide benefit for patients who have a less than ideal response to treatment with immune checkpoint inhibitors. We will also utilize mouse models to help further our understanding of how the gut bacteria interact with the immune system to fight against tumors. For this proposal, we have assembled a team of investigators with clinical expertise in the use of immunotherapy in the treatment of patients with advanced cancers (Drs. Lillian Siu, Marcus Butler, Rossanna Pezo, Anna Spreafico, and Jacques Raphael) and researchers with expertise in immunology and the microbiome (Drs. Alberto Martin and Bryan Coburn). By examining the gut microbiome in a large diverse population of patients with advanced cancers across multiple institutions, we will be able to identify key bacteria associated with immune checkpoint inhibitor response and/or toxicity.
Program
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
399105
Name
Martin Alberto
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
A multi institutional study evaluating the role of the gut microbiome on immune checkpoint inhibitor efficacy and toxicity in advanced solid tumors
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Breast Cancer; Colitis; Gut Microbiome; Head And Neck Cancers; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Solid Tumors
Abstract
Immune checkpoint inhibitors have improved survival for many patients with advanced cancers. However, these treatments do not work for all patients and we do not yet know how to best select patients for these treatments. In addition, many patients experience severe toxicities from immune checkpoint inhibitors. The type of bacteria in the human gut plays an important role in the immune system and may play an important role in determining whether a patient may benefit from treatment with immune checkpoint inhibitors and/or experiences toxicity. Our project will focus on further characterizing the gut bacteria involved in the activation of the immune system both in the response against tumors and in the development of toxicities. We will also test whether altering the bacteria in the gut may provide benefit for patients who have a less than ideal response to treatment with immune checkpoint inhibitors. We will also utilize mouse models to help further our understanding of how the gut bacteria interact with the immune system to fight against tumors. For this proposal, we have assembled a team of investigators with clinical expertise in the use of immunotherapy in the treatment of patients with advanced cancers (Drs. Lillian Siu, Marcus Butler, Rossanna Pezo, Anna Spreafico, and Jacques Raphael) and researchers with expertise in immunology and the microbiome (Drs. Alberto Martin and Bryan Coburn). By examining the gut microbiome in a large diverse population of patients with advanced cancers across multiple institutions, we will be able to identify key bacteria associated with immune checkpoint inhibitor response and/or toxicity.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Martin, Alberto; Butler, Marcus O; Pezo, Rossanna C; Siu, Lillian
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Gender & Health~ $25,000~ $0~